PBM Transparency Promises More Disclosure, Not Instant Relief
Employers are entering 2027 with a familiar problem: prescription drug spending keeps climbing, while the mechanisms that set those prices remain hard to see. The new PBM transparency requirements in the Consolidated Appropriations Act of 2026 aim to force pharmacy benefit managers to provide semi-annual reporting on rebates and overall spending, but the practical effect will lag behind the policy headline. For many plan sponsors, the immediate question is not whether disclosure improves in theory. The real question is whether disclosure can overcome a contracting structure built to discourage movement.
Healthcare premiums are projected to rise again, and employers are searching for ways to blunt the pressure without disrupting coverage. That makes pharmacy benefits an obvious target, because drug spending is one of the few large healthcare cost centers where plan design can still influence utilization, network routing, and vendor economics. Yet the market does not behave like an open marketplace. Price tags are hidden, rebate flows are opaque, and the entities controlling adjudication often control the data needed to compare alternatives.
Contract Terms Can Lock Employers Into High-Cost Arrangements
The first barrier is contractual. Many PBM agreements require long notice periods before termination, and larger custom contracts may demand as much as 12 months. In practice, that means an employer often has to make a switch decision before fully evaluating the exit costs, the clinical consequences, and the administrative burden of transition. If a rebate reconciliation payment or performance bonus has already been earned, early termination can force the employer to return it. The result is a financial penalty for trying to leave.
A second layer of exposure comes from rebate reconciliation itself. Standard contracts may allow PBMs to adjust previously reported rebate figures for 12 to 18 months after termination. That creates a delayed accounting window in which the employer still does not have a final picture of what was actually earned, retained, or clawed back. In a market built around volume and post hoc financial settlement, the lag is not a side issue. It is the mechanism.
The clinical implications are immediate.
Data Blockades Interfere With Safe PBM Transitions
Employers are entitled to claims data when a PBM contract ends, but the transfer is often shaped by contract language that favors the incumbent. The article describes several common tactics: expensive translation of proprietary data, extraction fees that may not surface until termination begins, and delays in transferring member eligibility files and prior authorization histories. Those delays are not merely administrative annoyances. They can interrupt medication access during the exact period when members are most vulnerable to disruption.
Specialty drugs make the problem more visible. A patient mid-therapy on a specialty medication may have an active prior authorization under the outgoing PBM, but that authorization does not automatically follow the member to the new vendor. The incoming PBM must re-adjudicate the case, and the coverage gap can land directly on the patient. When therapy is biologically time-sensitive, a delay in adjudication can mean a delay in treatment continuity, symptom control, and disease stability. In that setting, opaque data transfer becomes a clinical risk, not just a finance issue.
Specialty Drugs, GLP-1s, and Biosimilars Drive the Largest Savings Opportunity
Employers looking for lower costs are being pushed toward a narrower set of levers. The strongest starting point is specialty drug management, where carve-outs, site-of-care optimization, and alternative funding programs can reduce spend by 25% to 40% in some categories based on documented employer case results. Specialty pharmaceuticals concentrate cost because they often treat complex disease, require intensive handling, and carry high unit prices. Even modest changes in where and how these medications are dispensed can shift the economics materially.
GLP-1 management is another pressure point. Obesity-related GLP-1 programs that combine pharmacist coaching with behavioral support have reduced ongoing utilization while preserving outcomes. The key distinction is between management and suppression. A poorly designed program may simply move costs around or create discontinuation without a meaningful clinical framework. A structured approach can preserve therapeutic benefit while filtering out inefficient use.
Biosimilar-first policy is equally important. In many incumbent formularies, branded biologics remain preferred because rebate economics reward the higher list price rather than the lower net-cost alternative. When a biosimilar is clinically equivalent and materially less expensive, the employer’s task is to ensure the formulary reflects value rather than back-end incentives. The biology has already been settled. The contract has not.
Transparency Only Works If Employers Can Interpret the Numbers
The legislation’s reporting requirements will produce more data, but data alone does not equal control. Employers need the ability to understand claim-level rebates, audit administrative fees, trace formulary decisions back to clinical rationale, and verify whether specialty pharmacy routing is generating undisclosed margins. Without those capabilities, transparency becomes a document dump rather than an operating tool.
Independent pharmacy advisors and employer coalitions may become more important as the rules phase in. Their role is not to create another layer of jargon, but to translate the disclosures into concrete procurement decisions. Employers are not expected to become PBM actuaries overnight. They do need enough analytical clarity to see which dollars are being passed through, which are being retained, and which are being shifted into new labels.
What Employers Can Demand Before the Market Changes
The article lays out a straightforward standard for true transparency: rebates passed through in full and disclosed at the claim level, specialty pharmacy arrangements free of preferential routing, itemized and auditable administrative fees, and formulary decisions tied to clinical logic rather than manufacturer economics. Those benchmarks define a market in which comparison shopping is possible. They also reveal how far the current system still sits from that goal.
For employers, the most realistic path is to treat PBM review as both a clinical and financial exercise. Drug mix, utilization management, site-of-care policy, and prior authorization transfer all shape the final spend. So do contract timing, reconciliation rights, and data portability. A vendor that looks inexpensive on paper may still be expensive once the hidden costs are counted. A more expensive-looking arrangement may be cheaper if it prevents leakage through opaque rebate structures and avoids interruption during PBM transition.
The central obstacle remains unchanged: employers are trying to compare options in a market where the price tags are obscured and the exit ramps are narrow. The 2026 reform may improve visibility, but the first measurable effects will not arrive until 2027. Until then, plan sponsors will need to scrutinize contracts line by line, ask where their data lives, and determine whether their PBM is managing drug spend or merely relabeling it.